NBP10
An anti-RBD (SARS-CoV-2 Spike) antibody.
General information
NBP10 is a human naïve antibody identified for its affinity to SARS-CoV-2 Spike protein RBD using the yeast surface display technique. It does not inhibit the binding of RBD to host ACE2 receptor but manifests SARS-CoV-2 pseudovirus neutralization activity in vitro (Bell et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Neutralizing antibodies targeting the SARS‐CoV‐2 receptor binding domain isolated from a naïve human antibody library
Spike protein Biophysical assay In vitro Antibody |
in vitro binding assay; in vitro biophysical assay; HeLa/ACE2 cells; SARS-CoV2 pseudovirus | 3.88 | The antibody bound to SARS-CoV-2 Spike RBD in vitro and neutralized SARS-CoV-2 pseudotyped virus in HeLa cells overexpressing human ACE2 receptor with an IC50 of ca. 89 nM. Its epitope overlaps with the one of CR3022, an antibody from a SARS patient, which also cross-reacts with SARS-CoV-2 Spike protein. |
Feb/14/2021 |
